Telix Expands with Acquisition of ARTMS and Advanced Isotope Technology

Telix Pharmaceuticals Limited (ASX: TLX) has announced the acquisition of ARTMS Inc., a leader in cyclotron-based isotope production technology. This includes ARTMS' advanced QUANTM Irradiation System™ (QIS™) and a stockpile of rare metals for target production. The move aims to bolster Telix's supply chain, enhancing control over diagnostic isotopes like zirconium-89 (89Zr) and gallium-68 (68Ga). ARTMS' technology promises improved production efficiency and yields, especially for key isotopes like technetium-99m (99mTc) and copper-64 (64Cu).

The acquisition also supports Telix's pharmaceutical development, enabling advancements in kidney cancer imaging and therapeutic isotopes. Additionally, Telix will utilize ARTMS' production facility in Burnaby, BC, Canada, to expand research and production capabilities. Overall, this strategic move is expected to boost revenue and margins for Telix's product portfolio.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com